Lyon, France, June 26th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported today that the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC). The Press Release was issued by the study sponsor, Innate Pharma, and can be accessed on the company’s website. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ). OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). About NCT05742607 clinical trial MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. More information on the Phase 2 clinical trial is accessible online. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 Email : jeremy.bastid@orega-biotech.com  

Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming AACR annual meeting to be held on April 14 – 19, 2023 in Orlando, Florida.

Lyon, France, February 24th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, today announces the initiation of IPH5201 CD39 blocking antibody phase 2 trial (MATISSE). The study entitled “Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)” is an open-label, single-arm multicenter study (NCT05742607). As announced in 2022 (press release), the study will enroll 70 patients treated with IPH5201 (CD39 antibody) and Durvalumab (PDL1 antibody) plus standard of care chemotherapy before surgery followed by IPH5201 and Durvalumab. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 Email : jeremy.bastid@orega-biotech.com

The OREGA Biotech team wishes you all a wonderful holiday season, a Merry Christmas and a healthy and successful new year !

– PRESS RELEASE – For immediate release OREGA Biotech enters into an Exclusive License Agreement with Genmab for a novel immuno-oncology antibody program   OREGA Biotech grants Genmab rights to its first-in-class antibody against a novel, undisclosed immuno-oncology target Under the License Agreement with OREGA Biotech, Genmab will obtain the exclusive, worldwide right to develop and commercialize novel antibody therapeutics utilizing OREGA Biotech’s first-in-class antibody OREGA Biotech to receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments along with royalties on commercial sales.   Lyon, France, december 6th, 2022 – OREGA Biotech announces today an exclusive license agreement under which OREGA Biotech grants Genmab full, worldwide rights to its first-in-class immuno-oncology antibody program against a novel and undisclosed target. This license agreement results from a fruitful research collaboration between the two companies initiated in 2020. “We are thrilled to partner with Genmab, the renowned international biotechnology company“, said Jeremy Bastid, Chief Executive Officer of OREGA Biotech. “Our team discovered the role of this novel target in impairing the response to the PD1/PDL1 immune checkpoint inhibitors and demonstrated that a neutralizing antibody could reverse this effect and improve the response to cancer immunotherapy. We have been working very closely with Genmab’s scientific team for more than 2 years and we are convinced that their scientific skills and development capabilities will be of paramount importance to further develop this asset”, he added. Gilles Alberici, President of OREGA Biotech, further commented: “This licensing agreement marks another major step forward for our company and team after the successful out-licensing of our CD39 antibody program which is now entering phase 2 clinical trial. Given the track record of Genmab in developing and delivering innovations to the patients, we believe that Genmab is very well positioned to bring this novel antibody program to the clinic”, he added. Genmab will be responsible for the research, development, manufacturing and commercialization of the antibody. The parties will aim to enter into an additional agreement for OREGA Biotech to support Genmab’s preclinical research activities related to this antibody. “I would like to take the opportunity of this announcement to congratulate our scientists who did a fantastic work in advancing this antibody program and collaborating successfully with our Genmab’s colleagues despite the Covid-19 pandemic. I also would like to thank our partners from Inserm Transfert for their continued support during the licensing process”, Jeremy Bastid […]

Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming 37th SITC annual meeting to be held November 8-12 2022 (Boston, MA & virtual).

– PRESS RELEASE – For immediate release Progress of OREGA Biotech’s CD39 program: IPH5201 to advance into Phase 2 clinical trial in lung cancer   Lyon, France, June 6th, 2022 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, provides an update on its CD39 program: Innate Pharma announced that IPH5201, the CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, will advance into a Phase 2 clinical trial in lung cancer. About IPH5201 antibody IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech commenced the CD39 program at its inception in 2010, then entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody). Jeremy Bastid, Chief Executive Officer of OREGA Biotech, commented “We are very pleased that IPH5201 antibody is now progressing into a Phase 2 trial; this represents a major achievement for our company. Our academic cofounders are also very proud of having been involved in the discovery of the immunoregulatory role of the adenosine pathway in cancer, the components of which are now being targeted in multiple clinical trials”. Download the Press Release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President. Contact Jeremy Bastid, Chief Executive Officer Tel.: +33 (0)4 37 49 87 20 jeremy.bastid@orega-biotech.com   For more information: www.orega-biotech.com

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held on April 9-13 in New Orleans, Louisiana.

Today marks World Cancer Day 2022. With 10 million deaths per year, cancer is the second leading cause of death in the world. At OREGA Biotech we are committed to discover and develop novel cancer immunotherapies. We thank our collaborators and partners with whom we work hard to achieve this goal !

Professor Martine Bagot and Professor Armand Bensussan are rewarded for their research on the development of a targeted therapy, lacutamab, a monoclonal antibody targeting the tumor antigen KIR3DL2 for the treatment of patients with advanced, refractory and relapsed T cell lymphomas, particularly erythrodermic cutaneous T cell lymphomas. The Galien Prize here rewards two decades of research.

Jeremy BASTID, CEO of OREGA Biotech, will participate to the upcoming AACR annual meeting to be held virtually on April 10-15 and May 17-21, 2021.

From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours. Download abstract.

Jeremy Bastid, CEO of OREGA Biotech, will participate in the upcoming BIO-Europe conference to be held virtuallly on october 26-29, 2020. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. Jeremy will actively take part in this business event, registered under the name of the holding company, initiative OCTALFA.    

Orega Biotech announces the nomination of Jeremy Bastid as Chief Executive Officer (Directeur Général) effective as of July 1st, 2020. “I have worked with Jeremy since the inception of OREGA Biotech” commented Gilles Alberici, President of Octalfa and Chairman of OREGA Biotech. “He has played a prominent role in the development of the company, both on the R&D and the business aspects. No doubt that his promotion as CEO of OREGA Biotech will help the company to further grow”, he added. “I am honored to be appointed new CEO and look forward to leading OREGA Biotech with the support from our Board”, commented Jeremy Bastid. “I am thrilled to lead this remarkable team and I am grateful for our Board’s confidence”.

We review the current understanding on the IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. The emerging role of the IL-17B/IL-17RB pathway in cancer, published in  Frontiers in Immunology and co-authoring Jeremy Bastid, Cécile Dejou, Aurélie Docquier and Nathalie Bonnefoy (OREGA Biotech). The review article is accessible here.    

– PRESS RELEASE – For immediate release   First patient treated with anti-CD39 mAb IPH5201 on OREGA’s 10-year anniversary day   Lyon, France, March 10th, 2020 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, announced today that the first patient has been treated with the anti-CD39 humanized monoclonal antibody IPH5201. As chance would have it, it happened exactly 10 years to the day of inception of OREGA Biotech. “March 9th 2020 is marked special for us since our company was celebrating its 10th anniversary! In 10 years, we have come a long way and we have succeeded in the model we have chosen: that of discovering new targets and together with our partners bringing them to the patients. And on this 10‑year anniversary day the first patient has been dosed with IPH5201, the anti-CD39 monoclonal antibody that we developed in collaboration with Innate Pharma. A nice wink and real pride.”, said Jeremy Bastid, Chief Operating Officer of OREGA Biotech. Download the Press Release online.   About IPH5201 and NCT04261075 clinical trial IPH5201 is now being developed by Innate Pharma in collaboration with AstraZeneca (AZ). The multicenter, open-label, dose-escalation Phase I study (NCT04261075) will evaluate the safety, tolerability, antitumor activity, pharmacokinetics , pharmacodynamics and immunogenicity of IPH5201 alone, or in combination with AZ’s anti-PDL1 monoclonal antibody, durvalumab, with or without AZ’s anti-CD73 monoclonal antibody, oleclumab. More information on the Phase I clinical trial is accessible online.   About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. A new program is underway on a novel potent regulator of anti‑PD1 therapy response in anti‑PD1 refractory syngeneic mouse models. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.   Contact Jeremy Bastid, Chief Operating Officer Tel.: +33 (0)4 37 49 87 20 jeremy.bastid@orega-biotech.com   […]

A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response, published in Medecine Sciences and co-authoring Armand Bensussan, Jean-François Eliaou, Jérémy Bastid and Nathalie Bonnefoy (OREGA Biotech); Laurent Gros (INSERM); Carine Paturel and Ivan Perrot (Innate Pharma). The review article (in French) is accessible online.

Gilles Alberici, CEO and Jeremy Bastid, COO, will participate to the J.P. Morgan 38th Annual Healthcare Conference to be held 13-16 January 2020 in San Francisco, California, USA. The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

From all of us at OREGA Biotech we wish you a wonderful holiday season and Merry Christmas !

– PRESS RELEASE – For immediate release   Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies   Lyon, France, November 7th, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, will showcase preclinical efficacy data of a novel regulator of response to anti-PD1 and anti-CTLA4 immunotherapies. “We are thrilled to share the data on this program”, commented Jeremy Bastid, Chief Operating Officer. “The target was identified as a master regulator of anti-PD1 and anti-CTLA4 response in resistant mouse models using our in vivo genetic screening platform”. Dr Bonnefoy further commented on the preclinical antibody data : “Similarly to the KO mice, the candidate mAb was shown to turn non-responders or partial responders to PD1 or CTLA4 targeting therapies into complete responders with long term survival in several mouse models. We have compelling evidence suggesting that the mechanism of action involves the reduction of myeloid cell infiltration as well as profound alterations in the tumor draining lymph nodes.” The data will be presented on November 9th, 2019 during the 34th SITC annual meeting held at the Gaylord National Hotel & Convention Center in National Harbor, MD, USA. The full abstract #P286 “In vivo genetic screens in PD-1 resistant mouse models identified modulator of anti-PD1 response with relevance to pembrolizumab-treated human metastatic melanoma” has now been released and is accessible online. The poster will be displayed on Saturday, November 9th, 7:00 am – 8:30 pm. Our team, Jeremy Bastid, Chief Operating Officer of OREGA Biotech and Nathalie Bonnefoy, acting Chief Scientific Officer, will be present during the poster sessions 12:35 – 2:05 pm and 7:00 – 8:30 pm to discuss the data and provide more information on the program. Download the press release. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 and anti-CTLA4 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license agreements with larger biotech or […]

– PRESS RELEASE – For immediate release   First-in-class immune checkpoint inhibitor program presented by OREGA Biotech at SITC meeting Preclinical-stage blocking antibodies against a novel immune checkpoint; Increased response and survival to anti-PD1 in various PD1-resistant mouse models   Lyon, France, October 1st, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, announced today the presentation of the preclinical data of its novel immune checkpoint program at the upcoming SITC meeting to be held November 6 -10, National Harbor, Maryland (USA). The company has built an in vivo screening platform combining a knock-out (KO) approach against selected targets and several PD1 and/or CTLA4 resistant syngeneic mouse models aiming at identifying novel immune checkpoints and modulators of anti-PD1 or CTLA4 response. Using this target discovery approach, OREGA has already successfully identified CD39 as a novel immune checkpoint and the anti CD39 program was licensed to Innate Pharma in 2016 and has been further partnered with AstraZeneca/MedImmune in 2018. At SITC, we present for the first time a novel immuno-oncology target which plays a key role in anti- PD1 resistance. Whereas the used mouse models are broadly resistant to anti-PD1 mAb, the target KO markedly improved the efficacy of anti-PD1 therapy by increasing the response rates and the rate of complete vs partial responses, which translated into improved mouse survival. We report the generation of various human-mouse cross-reactive blocking antibodies to the target. The neutralizing antibodies mimicked the KO phenotype and markedly improved the response to anti-PD1 therapy in the preclinical mouse models. Analyzing human metastatic melanoma tumors prior to pembrolizumab treatment, OREGA scientists found a stepwise increased expression of the target, its receptor and the signaling pathway from complete responders (low expression) to partial responders and non-responders (high expression), suggesting that the identified target is relevant to clinics. Dr. Nathalie Bonnefoy, Deputy Director at Institut de Recherche en Cancérologie de Montpellier and acting Chief Scientific Officer at OREGA Biotech, commented: “It is now well established that only patients achieving complete response to anti-PD1 are the ones that derive long-term survival benefit from these immunotherapies. We designed a program aiming at identifying targets that may turn PD1 resistant tumors into PD1 sensitive tumors, improve response to these therapies and promote long term survival. We report for the first time preclinical data related to this novel immuno-oncology program. These data represent long term […]

OREGA Biotech – meet us at BIO-Europe 2019, Nov. 11 & 12  Lyon, France, September 23, 2019 – OREGA Biotech will participate in the upcoming BIO-Europe conference to be held in Hamburg, Germany, on November 11-13, 2019. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. OREGA Biotech will actively take part in this business event to promote our partnership-driven business model based on our in vivo screening platform aiming at discovering novel immune checkpoints and regulators of anti-PD1 response. Building on the successful partnering of our anti-CD39 antibodies (licensed to Innate Pharma and now partnered with AstraZeneca), we are open to discussion for our new program related to the discovery of a novel regulator of anti-PD1 response. Jeremy Bastid, Chief Operating Officer, will attend the BIO-Europe conference on November 11 & 12, 2019. About OREGA Biotech OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoints and regulators of anti-PD1 response. Anti-CD39 antibody were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with our targets prior entering into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO. For more information: www.orega-biotech.com  

Nathalie Bonnefoy, cofounder of OREGA Biotech and deputy director of Institut de Recherche en Cancérologie de Montpellier (IRCM), will inaugurate the first CyTOF Hyperion in France on September 18, 2019 at IRCM. Equipped with a very innovative technology, the CyTOF Hyperion will make it possible to explore tumor heterogeneity from a biopsy by very finely mapping tumor cells in their microenvironment, including the interactions with and between the immune cells. The CyTOF is a powerful tool for immuno-oncology studies. It reveals the structure of disease tissue at the single cell level and enables the characterization with up to 50 markers, from a single slide, of the spatial distribution and the cellular network with immune cells.

The publication of preclinical data of the CD39-blocking monoclonal antibody IPH5201 appears in the May 21, 2019 issue of the journal Cell Reports.  Read the full manuscript titled “Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies”

Jeremy BASTID, Chief Operating Officer, will attend the ASCO annual meeting to be held in Chicago, IL, May 31 – June 4, 2019.

Gilles Alberici, CEO, will attend the 2018 BIO-Europe meeting to be held in Copenhagen on November 2018, 5th to 7th.

Press Release Lyon, October 8, 2018 Interleukin-17 patent granted in Europe Lyon, France, October 8, 2018 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced the grant of patent EP2569335 by the European Patent Office. This patent covers IL-17A neutralizing antibodies for use as a therapeutic tool to increase the response to other chemotherapeutic agents. “The delivery of this European Patent is another important milestone for OREGA Biotech; it is the fifth issued patent related to our IL‑17 programs”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech. “Intellectual property is a key asset in OREGA’s target discovery programs. Our capacity to obtain broad claims covering novel cancer targets offers a valuable competitive advantage.” Read the press release.

On October 23, 2018, Innate Pharma announced that it had entered into a development collaboration and option for further co-development and co-commercialisation with AstraZeneca for its CD39 monoclonal antibody, IPH5201.

Jeremy Bastid, Chief Operating Officer, will attend the 2018 BIO International Convention, to be held in Boston, Massachusetts, June 4-7, 2018.

OREGA will present latest in vivo data of its IL-17B program at the upcoming AACR annual conference to be held in Washington DC. SESSION PO.IM02.06 – Cytokines: The First Modern Immunotherapies April 3, 2017, 8:00 AM – 12:00 PM 1602 / 10 – Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance

Press Release Lyon, France, April 18, 2017 –  OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification of allowance from the USPTO stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers antibodies binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. The related European Patent has already been granted in 2016. “The delivery of this US Patent is a significant milestone for OREGA Biotech’s IL-17 program. Our business model relies on our ability to discover novel targets and to generate IP rights over targets or broad claims such as functional epitopes”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech.  As of today, the patent portfolio of the company is composed of 9 families of patent applications owned or co-owned by OREGA biotech. Read the press release.

Press release OREGA Biotech strengthens its intellectual property OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification from the European Patent Office (EPO) stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers any antibody binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. This notification shortly follows another notice of allowance from the EPO which is about to deliver another strategic patent application held by INSERM and licensed to OREGA Biotech relating to antibodies that bind CD39. As of today, the patent portfolio of the company is composed of 8 families of patent applications owned or co-owned by OREGA biotech and one licensed patent. Read the press release.

Press release First-in-class CD39 Checkpoint Inhibitor presented at the AACR meeting Marseille and Lyon, April 19, 2016 – Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, USA. Poster #3222 presents IPH52, Innate’s humanized anti-CD39 blocking antibody. This novel antibody exhibits high affinity and specificity for CD39 and potently inhibits ATPase activity in in vitro assays and ex vivo models with patient biopsies. In a murine tumor model, treatment with anti-CD39 antibody results in a significant decrease in tumor volume, and improved survival. Poster #3218 presents for the first time the impact of CD39 disruption on the efficacy of other cancer therapeutics by comparing their effects in wildtype versus CD39 knock-out mice. The results revealed that CD39 deficiency sensitized to anti-PD1 treatment in animals that failed to respond to anti-PD-1 treatment. The antitumor efficacy of CD39 disruption is further improved when combined with an immunogenic chemotherapy. In animals bearing PD-1 insensitive tumors, combination of immunogenic chemotherapy, anti-PD1 antibody and CD39 disruption led to complete tumor eradication and long term protection (specific anti-tumor immunity) in most animals. The efficacy of an ADCC-inducing cytotoxic antibody was also improved in CD39 knock-out mice compared to wildtype. Nicolai Wagtmann, CSO of Innate Pharma, said: “Taken together, the data presented by Innate and our partner OREGA Biotech form a very promising body of evidence supporting the development of this new, first-in-class checkpoint inhibitor antibody. The results presented today raise exciting perspectives for the development of IPH52, both as single-agent and in combination with other checkpoint inhibitors, and we are eager to now take this first-in-class candidate forward into the preclinical development phases”. Jeremy Bastid, COO of OREGA Biotech, further commented: “CD39 mediates immunosuppression through a different mechanism than other immune checkpoints and may broadly impede the efficacy of cancer therapies. The exciting data released today using both antibody blockade and genetic CD39 deficiency shed light on the capacity of CD39 disruption to drive antitumor immune responses, either alone or in combination with PD-1 checkpoint blockers, ADCC antibodies and immunogenic chemotherapy, suggesting broad development potential”. For more information, read the press release.

Press Release Lyon, France, January 10th, 2016 OREGA Biotech announces Licensing Agreement with Innate Pharma OREGA Biotech today announces that it has entered into an exclusive licensing agreement with Innate Pharma by which OREGA grants Innate full worldwide rights to its program of first-in-class anti-CD39 immune checkpoint inhibitors. This license agreement arose from a fruitful research collaboration between the two companies initiated in 2014. Under the terms of the agreement, OREGA Biotech will receive undisclosed upfront payment, milestone payments for preclinical, clinical and regulatory achievements as well as royalties on net sales. For more information, read the press release.